Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 37

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Treatment approaches for patients with TP53-mutated mantle cell lymphoma

Lew, Thomas E, Minson, Adrian, Dickinson, Michael, Handunnetti, Sasanka M, Blombery, Piers, Khot, Amit, Anderson, Mary Ann, Ritchie, David, Tam, Constantine S, Seymour, John F·2023·The Lancet Haematology
DOI 10.1016/s2352-3026(22)00355-6
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(22)00355-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 73

  1. Eskelund, 2016, 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau, Br J Haematol, 175, 410, 10.1111/bjh.14241 · DOI · Paper page
  2. Le Gouill, 2017, Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma, N Engl J Med, 377, 1250, 10.1056/NEJMoa1701769 · DOI · Paper page
  3. Wang, 2022, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, N Engl J Med, 386, 2482, 10.1056/NEJMoa2201817 · DOI · Paper page
  4. Rummel, 2013, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet, 381, 1203, 10.1016/S0140-6736(12)61763-2 · DOI · Paper page
  5. Visco, 2019, Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death, Br J Haematol, 185, 940, 10.1111/bjh.15643 · doi:10.1111/bjh.15643
  6. Eskelund, 2020, Detailed long-term follow-up of patients who relapsed after the nordic mantle cell lymphoma trials: MCL2 and MCL3, HemaSphere, 5, e510, 10.1097/HS9.0000000000000510 · DOI
  7. Bond, 2021, Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy, Blood Adv, 5, 5179, 10.1182/bloodadvances.2021004765 · doi:10.1182/bloodadvances.2021004765
  8. Hoster, 2008, A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, 111, 558, 10.1182/blood-2007-06-095331 · DOI · Paper page
  9. Hoster, 2016, Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network, J Clin Oncol, 34, 1386, 10.1200/JCO.2015.63.8387 · doi:10.1200/jco.2015.63.8387
  10. Geisler, 2010, The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT), Blood, 115, 1530, 10.1182/blood-2009-08-236570 · doi:10.1182/blood-2009-08-236570
  11. Bernard, 2001, Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype, Leukemia, 15, 1785, 10.1038/sj.leu.2402272 · DOI · Paper page
  12. Greenwell, 2018, Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy, Cancer, 124, 2306, 10.1002/cncr.31328 · doi:10.1002/cncr.31328
  13. Cohen, 2015, Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma, Clin Lymphoma Myeloma Leuk, 15, 278, 10.1016/j.clml.2014.12.012 · doi:10.1016/j.clml.2014.12.012
  14. Sarkozy, 2014, Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index, Genes Chromosomes Cancer, 53, 106, 10.1002/gcc.22123 · doi:10.1002/gcc.22123
  15. Obr, 2018, TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma, Clin Lymphoma Myeloma Leuk, 18, 762, 10.1016/j.clml.2018.07.282 · doi:10.1016/j.clml.2018.07.282
  16. Halldórsdóttir, 2011, Impact of TP53 mutation and 17p deletion in mantle cell lymphoma, Leukemia, 25, 1904, 10.1038/leu.2011.162 · DOI
  17. Eskelund, 2017, TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy, Blood, 130, 1903, 10.1182/blood-2017-04-779736 · DOI · Paper page
  18. Delfau-Larue, 2015, High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma, Blood, 126, 604, 10.1182/blood-2015-02-628792 · DOI · Paper page
  19. Obr, 2020, A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma, Br J Haematol, 191, e103, 10.1111/bjh.17063 · doi:10.1111/bjh.17063
  20. Aukema, 2018, Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network, Blood, 131, 417, 10.1182/blood-2017-07-797019 · doi:10.1182/blood-2017-07-797019
  21. Nordström, 2014, SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma—a Nordic Lymphoma Group study, Br J Haematol, 166, 98, 10.1111/bjh.12854 · DOI
  22. Rodrigues, 2020, p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma, Br J Haematol, 191, 796, 10.1111/bjh.17023 · DOI
  23. Bomben, 2021, TP53 mutations with low variant allele frequency predict short survival in chronic lymphocytic leukemia, Clin Cancer Res, 27, 5566, 10.1158/1078-0432.CCR-21-0701 · DOI
  24. Yi, 2022, Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma, J Clin Invest, 132, 10.1172/JCI153283 · DOI
  25. Clot, 2018, A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome, Blood, 132, 413, 10.1182/blood-2018-03-838136 · DOI
  26. Hill, 2020, Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis, Blood Adv, 4, 2927, 10.1182/bloodadvances.2019001350 · DOI
  27. Jain, 2018, Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib, Br J Haematol, 183, 578, 10.1111/bjh.15567 · DOI
  28. Giné, 2022, Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial, J Clin Oncol, 40, 1196, 10.1200/JCO.21.02321 · DOI
  29. Wang, 2014, Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy, Blood, 124
  30. Dreyling, 2016, Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study, Lancet, 387, 770, 10.1016/S0140-6736(15)00667-4 · DOI · Paper page
  31. Rule, 2019, Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis, Haematologica, 104, e211, 10.3324/haematol.2018.205229 · DOI · Paper page
  32. Dreyling, 2022, Long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up, HemaSphere, 6, e712, 10.1097/HS9.0000000000000712 · DOI
  33. Song, 2020, Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase, Clin Cancer Res, 26, 4216, 10.1158/1078-0432.CCR-19-3703 · DOI · Paper page
  34. Song, 2022, Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study, Blood, 139, 3148, 10.1182/blood.2021014162 · DOI · Paper page
  35. Wang, 2022, Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial, Lancet Oncol, 23, 406, 10.1016/S1470-2045(21)00638-0 · DOI
  36. Anderson, 2016, The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism, Blood, 127, 3215, 10.1182/blood-2016-01-688796 · DOI · Paper page
  37. Davids, 2017, Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma, J Clin Oncol, 35, 826, 10.1200/JCO.2016.70.4320 · DOI · Paper page
  38. Eyre, 2019, Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after bruton tyrosine kinase inhibitor therapy, Haematologica, 104, e68, 10.3324/haematol.2018.198812 · DOI
  39. Lew, 2022, Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination, J Hematol Oncol, 15, 75, 10.1186/s13045-022-01295-3 · DOI
  40. Handunnetti, 2019, Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study, Blood, 134, 756, 10.1182/blood-2019-126619 · doi:10.1182/blood-2019-126619
  41. Tam, 2018, Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma, N Engl J Med, 378, 1211, 10.1056/NEJMoa1715519 · DOI · Paper page
  42. Agarwal, 2019, Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma, Nat Med, 25, 119, 10.1038/s41591-018-0243-z · DOI · Paper page
  43. Le Gouill, 2021, Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial, Blood, 137, 877, 10.1182/blood.2020008727 · DOI
  44. Kumar, 2021, Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen), Blood, 138
  45. Jerkeman, 2018, Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial, Lancet Haematol, 5, e109, 10.1016/S2352-3026(18)30018-8 · DOI
  46. Witzig, 2011, An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, Ann Oncol, 22, 1622, 10.1093/annonc/mdq626 · DOI · Paper page
  47. Goy, 2013, Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study, J Clin Oncol, 31, 3688, 10.1200/JCO.2013.49.2835 · DOI · Paper page
  48. Ruan, 2018, Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma, Blood, 132, 2016, 10.1182/blood-2018-07-859769 · DOI
  49. Albertsson-Lindblad, 2016, Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma, Blood, 128, 1814, 10.1182/blood-2016-03-704023 · DOI
  50. Fecteau, 2014, Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53, Blood, 124, 1637, 10.1182/blood-2014-03-559591 · DOI
  51. Shah, 2019, Use of lenalidomide plus rituximab in TP53-mutated mantle cell lymphoma (MCL) outside of clinic trial: the moffitt experience, Blood, 134
  52. Eskelund, 2018, Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma, Haematologica, 103, e541, 10.3324/haematol.2018.194399 · DOI
  53. Hambley, 2016, Bortezomib for the treatment of mantle cell lymphoma: an update, Ther Adv Hematol, 7, 196, 10.1177/2040620716648566 · DOI
  54. Fisher, 2006, Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma, J Clin Oncol, 24, 4867, 10.1200/JCO.2006.07.9665 · DOI · Paper page
  55. Friedberg, 2011, The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma, Blood, 117, 2807, 10.1182/blood-2010-11-314708 · doi:10.1182/blood-2010-11-314708
  56. Robak, 2015, Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma, N Engl J Med, 372, 944, 10.1056/NEJMoa1412096 · DOI · Paper page
  57. Lee, 2022, Phase ½ study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL), J Clin Oncol, 40
  58. Wang, 2022, Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers, NEJM Evid, 1, 10.1056/EVIDoa2100001 · doi:10.1056/evidoa2100001
  59. Feins, 2019, An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer, Am J Hematol, 94, S03, 10.1002/ajh.25418 · DOI · Paper page
  60. Iacoboni, 2022, Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma, Blood Adv, 6, 3606, 10.1182/bloodadvances.2021006922 · DOI
  61. Wang, 2022, Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study, J Clin Oncol
  62. Jain, 2022, Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real-world experience from the United States lymphoma CAR T consortium, J Clin Oncol, 40
  63. Palomba, 2020, Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in Transcend NHL 001, Blood, 136, 10, 10.1182/blood-2020-136158 · doi:10.1182/blood-2020-136158
  64. Lejeune, 2020, Bispecific, T-cell-recruiting antibodies in B-cell malignancies, Front Immunol, 11, 762, 10.3389/fimmu.2020.00762 · DOI
  65. Hutchings, 2021, Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial, J Clin Oncol, 39, 1959, 10.1200/JCO.20.03175 · DOI · Paper page
  66. Phillips, 2021, Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL), most of whom had failed prior Bruton's tyrosine kinase inhibitor (BTKi) therapy, Blood, 138, 130, 10.1182/blood-2021-148949 · doi:10.1182/blood-2021-148949
  67. Minson, 2021, Glofitamab CD20-TCB bispecific antibody, Leuk Lymphoma, 62, 3098, 10.1080/10428194.2021.1953016 · DOI
  68. Budde, 2022, Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study, J Clin Oncol, 40, 481, 10.1200/JCO.21.00931 · DOI · Paper page
  69. Bannerji, 2020, Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy, Blood, 136, 42, 10.1182/blood-2020-136659 · DOI
  70. Tam, 2009, Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma, Blood, 113, 4144, 10.1182/blood-2008-10-184200 · doi:10.1182/blood-2008-10-184200
  71. Rule, 2019, Allogeneic stem cell transplantation as part of front line therapy for mantle cell lymphoma, Br J Haematol, 184, 999, 10.1111/bjh.15723 · DOI
  72. Lin, 2019, Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations, Br J Haematol, 184, 1006, 10.1111/bjh.15721 · doi:10.1111/bjh.15721
  73. Lew, 2021, T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease, Bone Marrow Transplant, 56, 2857, 10.1038/s41409-021-01418-3 · DOI

Cited by

See all 37

Metadata

Authors
Lew, T. E., Minson, A., Dickinson, M., Handunnetti, S. M., Blombery, P., Khot, A., Anderson, M. A., Ritchie, D., Tam, C. S., & Seymour, J. F.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2023-02
Volume
10
Issue
2
Pages
e142-e154
ISSN
2352-3026
DOI
10.1016/s2352-3026(22)00355-6
Cited by
37
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment approaches for patients with TP53-mutated mantle cell lymphoma. https://app.cochat.ai/papers/10.1016/s2352-3026(22)00355-6
The paper
Lew, T. E., Minson, A., Dickinson, M., Handunnetti, S. M., Blombery, P., Khot, A., Anderson, M. A., Ritchie, D., Tam, C. S., & Seymour, J. F. (2023). Treatment approaches for patients with TP53-mutated mantle cell lymphoma. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(22)00355-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.